Navigation Links
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information please visit www.halozyme.com.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... that the CTNext board of directors has formed a Higher Education Entrepreneurship Advisory ... group composed of institution presidents and other high-ranking representatives from 35 higher education ...
(Date:6/20/2017)... ... 20, 2017 , ... Do More with OHAUS , With the launch of ... in the weighing industry, to extending its expertise across the entire laboratory to a ... and more, allowing for its customers to 'Do More' in the lab. ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey bees is like ... delivering pollen and nectar containing nutrients necessary for growth and survival. Better nutrition gives ... recent indicators point to a decline in honey bee health. Sick and weakened bees ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... secured a Series B round of financing in the amount of $6 million. ... private investors participated in the round. , The Series B funding will enable ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
Breaking Biology News(10 mins):